表紙
市場調查報告書

細胞週期蛋白依賴性激酶1:開發中產品分析

Cyclin Dependent Kinase 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 409621
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴性激酶1:開發中產品分析 Cyclin Dependent Kinase 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以細胞週期蛋白依賴性激酶1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供你涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴性激酶1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Astex Pharmaceuticals Inc
  • ChoDang Pharm Co Ltd
  • Presage Biosciences, Inc.
  • Tiziana Life Sciences Plc
  • Tragara Pharmaceuticals Inc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1995TDB

Summary

According to the recently published report 'Cyclin Dependent Kinase 1 - Pipeline Review, H2 2019'; Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 9 molecules.

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Cyclin-dependent kinase 1 or CDK1 is a protein encoded by CDK1gene. It plays a key role in promoting G2-M transition and regulating G1 progress and G1-S transition via association with multiple interphase cyclins. The kinase activity is controlled by cyclin accumulation and destruction through the cell cycle. The phosphorylation and dephosphorylation of this protein also play important regulatory roles in cell cycle control.

The report 'Cyclin Dependent Kinase 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3 and 1 respectively. Report covers products from therapy areas Oncology which include indications Colorectal Cancer, Glioblastoma Multiforme (GBM), Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Anaplastic Astrocytoma, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gliosarcoma, Marginal Zone B-cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Thymic Carcinoma and Triple-Negative Breast Cancer (TNBC).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23)
  • The report reviews Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
  • Adastra Pharmaceuticals Inc
  • Astex Pharmaceuticals Inc
  • BeyondBio Inc
  • ChoDang Pharm Co Ltd
  • MEI Pharma Inc
  • Neosome Life Sciences LLC
  • Rizen (Suzhou) Biosciences Co Ltd
  • Shanghai Haihe Biopharma Co Ltd
  • Tiziana Life Sciences Plc
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
  • AT-7519 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BEY-1107 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CD-650 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JS-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • milciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NEOS-518 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • voruciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • zotiraciclib citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
  • Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 03, 2019: MEI pharma announces updated clinical data from voruciclib
  • Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
  • Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
  • Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
  • Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
  • Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
  • May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
  • Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
  • Dec 03, 2018: Tiziana Completes patient enrollment in a phase 2a trial to evaluate tolerability and anti-tumor activity of Milciclib in hepatocellular carcinoma (HCC)
  • Dec 01, 2018: MEI Pharma presents preclinical data demonstrating Voruciclib synergistically induces apoptosis in combination with Venetoclax in acute myeloid leukemia cells at the 2018 American Society of Hematology Annual Meeting
  • Nov 01, 2018: MEI Pharma to present preclinical data of Voruciclib in combination with Venetoclax at ASH 2018
  • Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)
  • Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product
  • May 16, 2018: Tiziana Life Sciences Announces Interim Analysis Data from an Ongoing Phase 2a Trial of Milciclib Safety and Tolerability in Sorafenib-refractory or -intolerable, Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients
  • Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Adastra Pharmaceuticals Inc, H2 2019
  • Pipeline by Astex Pharmaceuticals Inc, H2 2019
  • Pipeline by BeyondBio Inc, H2 2019
  • Pipeline by ChoDang Pharm Co Ltd, H2 2019
  • Pipeline by MEI Pharma Inc, H2 2019
  • Pipeline by Neosome Life Sciences LLC, H2 2019
  • Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019
  • Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019
  • Pipeline by Tiziana Life Sciences Plc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top